Evidence map›Paper›PMID 42827153›Full record

ArticleNature chemical biology2026

Transcription remodeling and stalling by cisplatin-induced interstrand crosslinks.

Liulian Zhu, Weiqi Zhao, Lei Ye, Yankai Liu, Wenjing Deng, Bingshuo Qian, Xin Yang, Jun Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liulian Zhu *Department of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.
Weiqi Zhao *Department of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID http://orcid.org/0000-0002-2101-4941
Lei YeDepartment of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID http://orcid.org/0009-0000-0050-4397
Yankai LiuDepartment of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID http://orcid.org/0009-0000-2544-5231
Wenjing DengDepartment of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.
Bingshuo QianZhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0009-0432-716X
Xin YangDepartment of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID http://orcid.org/0000-0003-4267-9579
Jun XuDepartment of Genetics and Metabolism, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China. junxu2022@zju.edu.cn.ORCID http://orcid.org/0009-0001-1360-2778

Funding

Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) 2024C03151
6 · The paper itself

Abstract

Interstrand crosslinks (ICLs) block transcription by mechanisms that remain incompletely understood. Cisplatin induces ICLs that suppress transcription and contribute to its antitumor activity but these effects can be mitigated by transcription-coupled repair. Using reconstituted transcription systems and cryo-electron microscopy, we investigated how RNA polymerase II (Pol II) processes cisplatin-ICLs and captured eight sequential transcriptional states. Pol II unexpectedly remodels the crosslinked guanines into a novel conformation positioned above the bridge helix. This rearranged ICL prevents the damaged base from entering the active site and triggers Pol II backtracking following ATP misincorporation. Furthermore, Cockayne syndrome protein B, an ATP-dependent translocase that initiates transcription-coupled repair, neither promotes lesion bypass nor displaces stalled Pol II, thereby committing the lesion to transcription-coupled repair. These findings identify Pol II as a structural remodeler of cisplatin-ICLs and reveal how the remodeled lesion stalls transcription, providing insight into cellular responses to platinum-based chemotherapy.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.